• The Phase I clinical trial will evaluate a proprietary drug candidate formulated using Cyprumed’s oral tablet technology, marking the first Cyprumed technology program to enter human clinical development
  • The milestone triggers a payment to Cyprumed under the companies’ existing collaboration agreement